SLC5A2 and chronic kidney disease: The efficacy of these drugs extends across chronic kidney disease, and it is imperative to ensure the appropriate implementation of SGLT-2 inhibitor therapy use across these populations to improve event-free survival and reduce the associated healthcare costs.